Nebulizer maker HCmed has announced the appointment of Chris Vernall as its new Executive VP of Business Development. Vernall started his career as an inhalation scientist at Nanopharm and later returned to Nanopharm as Director of Business Development after a stint at Intertek. He then served in a similar role at Vectura before returning to Intertek in 2022 as Commercial Director. During his time at Intertek, Vernall was co-chair of the IPAC-RS Inhaled and Nasal Biologics Steering Committee.
HCmed, which is based in Taipei, opened a laboratory in the UK in 2022, and Vernall will be based in the UK. The company currently has two handheld vibrating mesh nebulizer platforms, the Pulmogine continuous nebulizer and the AdheResp breath-activated nebulizer. In 2022, HCmed joined with Formosa Laboratories and Formosa Pharmaceuticals to form a CDMO for inhaled drugs using its nebulizer technology.
The HCmed announcement says of Vernall, “His deep understanding of respiratory drug development, coupled with his commercial expertise, makes him a valuable addition to HCmed Innovations as the company continues to expand its global reach and network of partners.”
Read the HCmed announcement
